Highlights from AUC3 by Shilpa Gupta
The Advanced Urologic Cancer Consensus Conference (AUC3), held on January 23-24, 2025, was a dynamic and interactive two-day live meeting. During the conference, selected panel members from multiple disciplines debated and voted on diagnostic and management strategies for kidney and bladder cancer.
Following the discussions, the conference directors and panel members collaborated to develop and draft a consensus guide, providing valuable insights into the latest approaches in urologic cancer care. The event took place at the Kimpton EPIC Hotel in Miami, Florida.
Shilpa Gupta, Director of Genitourinary Oncology at Cleveland Clinic, shared about this conference on social media.
“Kick off the inaugural AUC3 consensus meeting to brainstorm and develop guidelines for advanced kidney cancer and bladder cancer. Excited to be here with distinguished friends/colleagues from around the world! Great to start with our patient advocate Bryan Lewis to remind us why we do what we do!”
Not everything that looks like clear cell RCC is clear cell
“Sumantha Pal and Bradley McGregor moderate an excellent session addressing challenging issues with variant history RCC. Great to have the brightest minds tackle this topic at the AUC3 mtg! Not everything that looks like clear cell RCC is clear cell. Need an expert pathology review for cases to properly classify.”
“After an amazing day 1 of AUC3 covering data gaps and topics in RCC, we are ready for day 2 to cover Urothelial cancer. The amazing patient advocate Rick Bangs shares his journey and reminds us why we do what we do! Packed room full of experts from around the world to brainstorm guidelines for challenging topics.”
Josh Meeks kicking off the special NMIBC session
“Day 2 Urothelial cancer Amazing job by Josh Meeks kicking off the special NMIBC session addressing the key Q of mgmt of tx naive NMIBC during BCG shortage. Novel trials and alternative agents/BCG strains and alternative dosing may be the answer.”
Andrea Necchi about variant histologies in NMIBC
“Day 2 Urothelial cancer:
The amazing Andrea Necchi talks about variant histologies in NMIBC, data gaps, trial designs and how to close the access/disparities gap globally.”
Overview on ctDNA and other biomarkers in UC
“Day 2 Urothelial Cancer Always a delight to listen to the one and only Tom Powles. Excellent overview on ctDNA and other biomarkers in UC and data from other cancers. Great analogy to desert and oil fields! A lot of work ahead of us to brainstorm and try to close the knowledge gaps in UC with the help of experts around the world gathered in Miami.”
Co-chairing the session with Andrea Apolo
“Glad to co-chair the session with Andrea Apolo on considerations for special populations with UC AUC3 Day 2 Urothelial ca:
David H Aggen makes a case against single agent pembro and for EV pembro duo with analogies to the famous duos like Brian Rini and Tom Powles.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023